Biotechnology company and drug-delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its pioneering-drug delivery platform DehydraTECH(TM), which improves the speed, taste and delivery of bioactive compounds, including nicotine and cannabinoids. A recent article discussing the company reads, “Furthermore, the DehydraTECH drug delivery platform increases bio-absorption by up to 10 times and lessens the time of onset, with effects being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without the platform. In addition, the technology is patent protected for cannabidiol (CBD) and all other nonpsychoactive cannabinoids. Patents are also granted for THC (tetrahydrocannabinol), other psychoactive compounds and NSAIDs (nonsteroidal, anti-inflammatory drugs), as well as nicotine and other molecules. . . . Lexaria Bioscience has partnered with one of the world’s largest tobacco companies to fund the research and development of the DehydraTECH technology for oral nicotine. Through wholly owned subsidiary Lexaria Nicotine LLC, Lexaria is working to propel innovation in oral, reduced-risk nicotine consumer products utilizing DehydraTECH (http://cnw.fm/lR3Sl).”
To view the full article, visit http://cnw.fm/dG13x
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000
For more information please visit https://www.CannabisNewsWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor